Related Experiment Video

Updated: Oct 28, 2025

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
09:08

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer

Published on: January 12, 2020

6.9K

IFN-γ inhibits ovarian cancer progression via SOCS1/JAK/STAT signaling pathway

A H Gao1, Y R Hu2, W P Zhu3

  • 1Department of Gynaecology and Obstetrics, The Second Affiliated Hospital of Soochow University, No.1055 sanxiang road, Suzhou, 215004, China.

Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
|July 18, 2021
PubMed
Abstract

Insights

Interferon-gamma (IFN-γ) inhibits ovarian cancer (OC) progression by enhancing SOCS1 expression, which suppresses STAT3 and STAT5 phosphorylation, thereby reducing cell multiplication and invasion.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Ovarian cancer (OC) is a prevalent malignancy with complex mechanisms.
  • Interferon-gamma (IFN-γ), a key cytokine, shows anti-tumor potential in various cancers.
  • The specific role and molecular pathways of IFN-γ in OC remain unclear.

Purpose of the Study:

  • To investigate the functional role of IFN-γ in ovarian cancer cell lines.
  • To elucidate the underlying molecular mechanisms by which IFN-γ affects OC progression.

Main Methods:

  • OC cell lines (SKOV3, OVCAR3) were treated with varying concentrations of IFN-γ.
  • Cell proliferation, apoptosis, cell cycle, migration, and invasion were assessed.
  • mRNA and protein expression, including phosphorylation levels of key signaling molecules (STATs, SOCS1), were analyzed via qRT-PCR and Western blot.

Main Results:

  • IFN-γ significantly suppressed OC cell proliferation, migration, and invasion in a dose-dependent manner.
  • IFN-γ treatment led to increased apoptosis and G0/G1 cell cycle arrest.
  • IFN-γ upregulated SOCS1 expression and inhibited STAT3 and STAT5 phosphorylation; SOCS1 knockdown partially reversed these effects.

Conclusions:

  • IFN-γ exhibits potent anti-cancer effects against ovarian cancer cells.
  • The mechanism involves IFN-γ-induced SOCS1 upregulation, leading to the suppression of STAT3 and STAT5 phosphorylation.
  • IFN-γ represents a potential therapeutic agent for ovarian cancer.
Keywords:
IFN-γJAK/STAT signaling pathwayOvarian cancerSOCS1

More Related Videos

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-107:59

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1

Published on: December 5, 2020

2.7K
Assessment of Ovarian Cancer Spheroid Attachment and Invasion of Mesothelial Cells in Real Time14:25

Assessment of Ovarian Cancer Spheroid Attachment and Invasion of Mesothelial Cells in Real Time

Published on: May 20, 2014

17.5K

Related Concept Videos

TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
8.1K
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
8.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.0K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
9.7K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.2K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.7K